Organon Pharma Indonesia Tbk. vs Widodo Makmur Unggas Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Widodo Makmur Unggas Tbk. trades at Rp50 (market cap 647.06B, 857.7K 24h volume). The key difference: Widodo Makmur Unggas Tbk. is far larger — about 6.2× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SCPI | WMUU | |
|---|---|---|
Market Cap | 104.4B | 647.06B |
Volume | — | 857.7K |
Lot | — | 8.58K |
Turnover | — | 42.89M |
Average Price | — | 50 |
Value | — | 42.89M |
Indicative Equilibrium Price | — | 50 |
Indicative Equilibrium Volume | — | 22 |
Trailing returns across standard periods
Latest headlines on both assets
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →PT Widodo Makmur Unggas Tbk (the Company) established by the name of PT Pakan Makmur Perkasa based on Deed of Establishment of Company No. 08 dated March 4, 2015 of Rini Lestari, S.H., Notary in Depok. The Company commenced commercial operations in February 2017.
Read more on WMUU →